Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Sandoz to commercialize Pear's reSET digital therapeutics to combat substance abuse

Executive Summary

Sandoz International GMBH will lead the commercialization of Pear Therapeutics Inc.'s reSET for substance use disorder (SUD) and reSET-O for opioid use disorder (OUD).
Deal Industry
  • Digital Health
  • Medical Devices
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register